用于神经科学研究的骆驼源纳米体的开发、筛选和验证

Q2 Neuroscience Current Protocols in Neuroscience Pub Date : 2020-11-13 DOI:10.1002/cpns.107
Clara E. Gavira-O'Neill, Jie-Xian Dong, James S. Trimmer
{"title":"用于神经科学研究的骆驼源纳米体的开发、筛选和验证","authors":"Clara E. Gavira-O'Neill,&nbsp;Jie-Xian Dong,&nbsp;James S. Trimmer","doi":"10.1002/cpns.107","DOIUrl":null,"url":null,"abstract":"<p>Nanobodies (nAbs) are recombinant antigen-binding variable domain fragments obtained from heavy-chain-only immunoglobulins. Among mammals, these are unique to camelids (camels, llamas, alpacas, etc.). Nanobodies are of great use in biomedical research due to their efficient folding and stability under a variety of conditions, as well as their small size. The latter characteristic is particularly important for nAbs used as immunolabeling reagents, since this can improve penetration of cell and tissue samples compared to conventional antibodies, and also reduce the gap distance between signal and target, thereby improving imaging resolution. In addition, their recombinant nature allows for unambiguous definition and permanent archiving in the form of DNA sequence, enhanced distribution in the form of sequences or plasmids, and easy and inexpensive production using well-established bacterial expression systems, such as the IPTG induction method described here. This article will review the basic workflow and process for developing, screening, and validating novel nAbs against neuronal target proteins. The protocols described make use of the most common nAb development method, wherein an immune repertoire from an immunized llama is screened via phage display technology. Selected nAbs can then be taken through validation assays for use as immunolabels or as intrabodies in neurons. © 2020 Wiley Periodicals LLC.</p><p>This article was corrected on 26 June 2021. See the end of the full text for details.</p><p><b>Basic Protocol 1</b>: Total RNA isolation from camelid leukocytes</p><p><b>Basic Protocol 2</b>: First-strand cDNA synthesis; V<sub>H</sub>H and V<sub>H</sub> repertoire PCR</p><p><b>Basic Protocol 3</b>: Preparation of the phage display library</p><p><b>Basic Protocol 4</b>: Panning of the phage display library</p><p><b>Basic Protocol 5</b>: Small-scale nAb expression</p><p><b>Basic Protocol 6</b>: Sequence analysis of selected nAb clones</p><p><b>Basic Protocol 7</b>: Nanobody validation as immunolabels</p><p><b>Basic Protocol 8</b>: Generation of nAb-pEGFP mammalian expression constructs</p><p><b>Basic Protocol 9</b>: Nanobody validation as intrabodies</p><p><b>Support Protocol 1</b>: ELISA for llama serum testing, phage titer, and screening of selected clones</p><p><b>Support Protocol 2</b>: Amplification of helper phage stock</p><p><b>Support Protocol 3</b>: nAb expression in amber suppressor <i>E. coli</i> bacterial strains</p>","PeriodicalId":40016,"journal":{"name":"Current Protocols in Neuroscience","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/cpns.107","citationCount":"3","resultStr":"{\"title\":\"Development, Screening, and Validation of Camelid-Derived Nanobodies for Neuroscience Research\",\"authors\":\"Clara E. Gavira-O'Neill,&nbsp;Jie-Xian Dong,&nbsp;James S. Trimmer\",\"doi\":\"10.1002/cpns.107\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Nanobodies (nAbs) are recombinant antigen-binding variable domain fragments obtained from heavy-chain-only immunoglobulins. Among mammals, these are unique to camelids (camels, llamas, alpacas, etc.). Nanobodies are of great use in biomedical research due to their efficient folding and stability under a variety of conditions, as well as their small size. The latter characteristic is particularly important for nAbs used as immunolabeling reagents, since this can improve penetration of cell and tissue samples compared to conventional antibodies, and also reduce the gap distance between signal and target, thereby improving imaging resolution. In addition, their recombinant nature allows for unambiguous definition and permanent archiving in the form of DNA sequence, enhanced distribution in the form of sequences or plasmids, and easy and inexpensive production using well-established bacterial expression systems, such as the IPTG induction method described here. This article will review the basic workflow and process for developing, screening, and validating novel nAbs against neuronal target proteins. The protocols described make use of the most common nAb development method, wherein an immune repertoire from an immunized llama is screened via phage display technology. Selected nAbs can then be taken through validation assays for use as immunolabels or as intrabodies in neurons. © 2020 Wiley Periodicals LLC.</p><p>This article was corrected on 26 June 2021. See the end of the full text for details.</p><p><b>Basic Protocol 1</b>: Total RNA isolation from camelid leukocytes</p><p><b>Basic Protocol 2</b>: First-strand cDNA synthesis; V<sub>H</sub>H and V<sub>H</sub> repertoire PCR</p><p><b>Basic Protocol 3</b>: Preparation of the phage display library</p><p><b>Basic Protocol 4</b>: Panning of the phage display library</p><p><b>Basic Protocol 5</b>: Small-scale nAb expression</p><p><b>Basic Protocol 6</b>: Sequence analysis of selected nAb clones</p><p><b>Basic Protocol 7</b>: Nanobody validation as immunolabels</p><p><b>Basic Protocol 8</b>: Generation of nAb-pEGFP mammalian expression constructs</p><p><b>Basic Protocol 9</b>: Nanobody validation as intrabodies</p><p><b>Support Protocol 1</b>: ELISA for llama serum testing, phage titer, and screening of selected clones</p><p><b>Support Protocol 2</b>: Amplification of helper phage stock</p><p><b>Support Protocol 3</b>: nAb expression in amber suppressor <i>E. coli</i> bacterial strains</p>\",\"PeriodicalId\":40016,\"journal\":{\"name\":\"Current Protocols in Neuroscience\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-11-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/cpns.107\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Protocols in Neuroscience\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cpns.107\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Neuroscience\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Protocols in Neuroscience","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cpns.107","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Neuroscience","Score":null,"Total":0}
引用次数: 3

摘要

纳米体是重组抗原结合可变结构域片段,从纯重链免疫球蛋白中获得。在哺乳动物中,这些是骆驼科动物(骆驼、大羊驼、羊驼等)所特有的。纳米体由于其在各种条件下的高效折叠和稳定性,以及它们的小尺寸,在生物医学研究中有很大的应用。后一种特性对于用作免疫标记试剂的nab尤为重要,因为与常规抗体相比,这可以提高细胞和组织样品的穿透性,并且还可以减少信号和靶标之间的间隙距离,从而提高成像分辨率。此外,它们的重组性质允许以DNA序列的形式进行明确的定义和永久存档,以序列或质粒的形式增强分布,以及使用完善的细菌表达系统(如本文描述的IPTG诱导方法)轻松廉价地生产。本文将回顾开发、筛选和验证针对神经元靶蛋白的新型nab的基本工作流程和过程。所描述的方案利用了最常见的nAb开发方法,其中通过噬菌体展示技术筛选来自免疫骆驼的免疫库。然后,选定的nab可以通过验证试验作为免疫标记或作为神经元中的体内抗体。©2020 Wiley Periodicals llc .本文于2021年6月26日更正。详情见全文末尾。基本方案1:从骆驼白细胞中分离总RNA基本方案2:第一链cDNA合成;VHH和VH库pcr基本方案3:噬菌体展示库的制备基本方案4:噬菌体展示库的规划基本方案5:小规模nAb表达基本方案6:选定nAb克隆的序列分析基本方案7:纳米体作为免疫标签的验证基本方案8:nAb- pegfp哺乳动物表达构建的生成基本方案9:纳米体作为体内体的验证支持方案1:ELISA用于羊驼血清检测、噬菌体滴度和选定克隆的筛选支持方案2:辅助噬菌体的扩增支持方案3:琥珀色抑制大肠杆菌菌株nAb的表达
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Development, Screening, and Validation of Camelid-Derived Nanobodies for Neuroscience Research

Nanobodies (nAbs) are recombinant antigen-binding variable domain fragments obtained from heavy-chain-only immunoglobulins. Among mammals, these are unique to camelids (camels, llamas, alpacas, etc.). Nanobodies are of great use in biomedical research due to their efficient folding and stability under a variety of conditions, as well as their small size. The latter characteristic is particularly important for nAbs used as immunolabeling reagents, since this can improve penetration of cell and tissue samples compared to conventional antibodies, and also reduce the gap distance between signal and target, thereby improving imaging resolution. In addition, their recombinant nature allows for unambiguous definition and permanent archiving in the form of DNA sequence, enhanced distribution in the form of sequences or plasmids, and easy and inexpensive production using well-established bacterial expression systems, such as the IPTG induction method described here. This article will review the basic workflow and process for developing, screening, and validating novel nAbs against neuronal target proteins. The protocols described make use of the most common nAb development method, wherein an immune repertoire from an immunized llama is screened via phage display technology. Selected nAbs can then be taken through validation assays for use as immunolabels or as intrabodies in neurons. © 2020 Wiley Periodicals LLC.

This article was corrected on 26 June 2021. See the end of the full text for details.

Basic Protocol 1: Total RNA isolation from camelid leukocytes

Basic Protocol 2: First-strand cDNA synthesis; VHH and VH repertoire PCR

Basic Protocol 3: Preparation of the phage display library

Basic Protocol 4: Panning of the phage display library

Basic Protocol 5: Small-scale nAb expression

Basic Protocol 6: Sequence analysis of selected nAb clones

Basic Protocol 7: Nanobody validation as immunolabels

Basic Protocol 8: Generation of nAb-pEGFP mammalian expression constructs

Basic Protocol 9: Nanobody validation as intrabodies

Support Protocol 1: ELISA for llama serum testing, phage titer, and screening of selected clones

Support Protocol 2: Amplification of helper phage stock

Support Protocol 3: nAb expression in amber suppressor E. coli bacterial strains

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current Protocols in Neuroscience
Current Protocols in Neuroscience Neuroscience-Neuroscience (all)
自引率
0.00%
发文量
0
期刊介绍: Current Protocols in Neuroscience is a one-stop resource for finding and adapting the best models and methods for all types of neuroscience experiments. Updated every three months in all formats, CPNS is constantly evolving to keep pace with the very latest discoveries and developments. A year of these quarterly updates is included in the initial CPNS purchase price.
期刊最新文献
Simultaneous Ca2+ Imaging and Optogenetic Stimulation of Cortical Astrocytes in Adult Murine Brain Slices Automated Two-Chamber Operon ID/ED Task for Mice Automated Quantification of Mitochondrial Fragmentation in an In Vitro Parkinson's Disease Model. Whole-Brain Image Analysis and Anatomical Atlas 3D Generation Using MagellanMapper. A Guide to Fluorescence Lifetime Microscopy and Förster's Resonance Energy Transfer in Neuroscience
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1